New CBD & THC Cannabis Oils Now Shipping To Australia From Canada
New CBD & THC Cannabis Oils Now Shipping To Australia From Canada
MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) announced on Wednesday that Canadian-produced GMP Beacon Medical cannabis oil and inhalation cartridges have launched in the Australian medical marijuana market.
醫療藥業實驗室公司多倫多證券交易所股票代碼：Labs)(場外交易代碼：MEDIF)(多倫多證券交易所股票代碼：MLZ)週三宣佈，加拿大生產的GMP烽火醫療我大麻澳大利亞醫用大麻市場已經推出了油盒和吸入盒。
The cannabis oil portfolio features a high CBD Isolate (THC-free) oil, a balanced oil and a THC dominant full spectrum oil made with Beacon's popular medical flower strains.
大麻油產品組合以高CBD分離(不含THC)油、平衡油和由Beacon廣受歡迎的藥用花卉品種製成的THC優勢全光譜油為特色。
The inhalation cartridges include flavor-forward options popular with patients in the Canadian market and strain-specific full-spectrum cartridges that utilize flower varieties already favored by Beacon Medical patients.
這些吸入藥盒包括在加拿大市場上廣受患者歡迎的香料轉發選項，以及使用Beacon Medical患者已經喜歡的花卉品種的菌株特定全光譜藥盒。
With Beacon Medical's Pink Kush and GSC products available in flower, oil and inhalation formats, the company provides physicians and patients with three delivery methods to consume the same full spectrum strains.
Beacon Medical的粉色庫什和GSC產品有花、油和吸入三種形式，該公司為醫生和患者提供了三種給藥方式，以消耗相同的全譜菌株。
Deliveries of inhalation cartridges to patients kicked off this week, and cannabis oils are scheduled to ship from Canada this week as well, the Toronto, Canada-based company said in a press release.
本週開始向患者交付吸入彈這家總部位於加拿大多倫多的公司在一份新聞稿中表示，大麻油也計劃本週從加拿大發貨。
MediPharm holds an Australian GMP license from the Therapeutic Goods Administration (TGA), complemented by its GMP status from Health Canada (Drug Establishment License) and the US FDA.
MediPharm擁有澳大利亞治療藥品管理局(TGA)頒發的GMP許可證，並獲得加拿大衛生部(藥品機構許可證)和美國FDA的GMP資格。
In July 2023, the TGA revised import and medical cannabis regulations, requiring all products to meet cGMP standards.
2023年7月，TGA修訂了進口和醫用大麻法規，要求所有產品都符合cGMP標準。
What's Next
接下來是什麼？
Beacon Medical Australia plans to educate and collect feedback on these products from physicians and patients with the help of its recently expanded medical scientific liaison field team.
Beacon Medical Australia計劃在其最近擴大的醫療科學聯絡領域團隊的幫助下，教育和收集醫生和患者對這些產品的反饋。
This allows MediPharm Labs further access to the Australian medical cannabis market.
這使得MediPharm Labs能夠進一步進入澳大利亞醫用大麻市場。
Want to watch our Cannabis Capital Conference live? For existing subscribers you can get direct access through our research platform. For new users, you can get instant access here!
想看我們的大麻之都大會現場直播嗎？對於現有的訂閱者，您可以直接訪問通過我們的研究平臺。對於新用戶，您可以獲得即時訪問此處好了！
MEDIF Price Action
MEDIF價格行動
MediPharm's shares traded 0.2686% higher at $0.056 per share at the time of writing on Wednesday morning.
週三上午，在撰寫本文時，醫藥集團的股價上漲了0.2686%，至每股0.056美元。
Related News
相關新聞
- MediPharm Labs Breaks Free From Royalty Agreement, What It Means & What's Next
- Could Medical Cannabis Be The Answer For Fibromyalgia? Here's What New Study Found
- Cannabinoid-Focused Pharma Stock Slides On Q2 Earnings Report, Here Are The Details
- MediPharm Delivers Cannabis Clinical Trial Material To US Research Partner And Provides Update On FDA Status
- 醫藥實驗室打破版稅協定，意味著什麼&下一步是什麼
- 醫用大麻是治療纖維肌痛的良藥嗎？以下是新研究的發現
- 專注於大麻類藥物的製藥股第二季度收益報告幻燈片，以下是詳細資訊
- MediPharm向美國研究合作夥伴提供大麻臨床試驗材料並提供FDA最新情況
Photo: Courtesy of Kimzy Nanney on Unsplash
圖片：由Kimzy Nanney在UnSplash上提供